Market cap per employee, and rate of R&D spending, for large pharmaceutical companies
Among large bio-pharmaceutical firms, Gilead is an outlier in terms of market cap per employee.
The data is also presented in the table below.
| Firm | R&D spending as percent of 2011 2nd quarter revenue | Market Cap, billions of USD (August 7, 2011) | Number of Employees | Mrk Cap /employees |
| Johnson & Johnson | 11.3% | $ 171.90 | 115,000 | $ 1,494,783 |
| Roche | 17.9% | $ 146.50 | 80,653 | $ 1,816,423 |
| Novartis | 16.1% | $ 131.16 | 119,418 | $ 1,098,327 |
| Pfizer | 13.2% | $ 138.19 | 110,600 | $ 1,249,458 |
| Merck | 15.9% | $ 97.88 | 91,000 | $ 1,075,604 |
| Sanofi | 14.3% | $ 95.99 | 101,575 | $ 945,016 |
| Abbott | 10.8% | $ 77.74 | 90,000 | $ 863,778 |
| AstraZeneca | 12.9% | $ 60.22 | 61,100 | $ 985,597 |
| Amgen | 21.0% | $ 48.16 | 17,100 | $ 2,816,374 |
| BMS | 17.0% | $ 46.79 | 27,000 | $ 1,732,963 |
| Lilly | 20.2% | $ 41.95 | 38,065 | $ 1,102,062 |
| Gilead | 13.2% | $ 29.32 | 4,000 | $ 7,330,000 |